Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Novacyt ( (FR:ALNOV) ) is now available.
Novacyt S.A. has provided a monthly update on its liquidity agreement with Invest Securities SA, detailing the trading of its ordinary shares. During October 2025, Invest Securities purchased and sold shares within a specified price range, and the company reported a total of 112,913 treasury shares. The total number of ordinary shares stands at 70,626,248, which is relevant for shareholder interest notifications. The liquidity agreement, governed by French law, allows Invest Securities to provide liquidity services independently, with shareholder-approved terms for share purchases.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services, primarily focused on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation to deliver solutions across sectors including human health, animal health, and environmental. Novacyt operates in three business segments: Clinical, Instrumentation, and Research Use Only, and has a commercial presence in over 65 countries.
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.